Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Adrian Ceccato (Ituzaingo, Argentina), Adrian Ceccato, Miquel Ferrer, Albert Gabarrus, Oriol Sibilla, Eva Polverino, Catia Cilloniz, Carlos Agusti, Francisca Lopez, Michael Niederman, Antoni Torres. Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia. Eur Respir J 2016; 48: Suppl. 60, 3328

Member's Comments

No comment yet.

Related content which might interest you: Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Factors affecting treatment success in community acquired pneumonia (CAP) Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Surfactant-enforced treatment of pseudomonas-induced pneumonia Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Could the early administration of antibiotics before admission improve the prognosis of pneumonia? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009